Comparison of human papillomavirus testing strategies for triage of women referred with low-grade cytological abnormalities.

AIM To compare triage strategies using different human papillomavirus (HPV) consensus and genotyping tests and a p16(INK4a) test. METHODS 1228 women referred with a borderline or single mildly dyskaryotic smear. Samples were taken at colposcopy using PreservCyt. Tests included Hybrid Capture 2, Abbott RealTime PCR, BD HPV, Cobas 4800, PreTect HPV-Proofer, APTIMA and p16(INK4a). Results were based on the worst histology within 9 months. RESULTS 97/1228 (7.9%) women had CIN3+ (203/1228 (17%) CIN2+). HPV testing alone using Hybrid Capture 2, Abbott RealTime PCR, BD HPV, Cobas 4800 or APTIMA had a sensitivity for CIN3+ ranging from 99.0% to 100.0% and specificity for <CIN2 from 23.3% to 34.7%. p16(INK4a) had a sensitivity of 86.8% and specificity of 50.7%. PreTect HPV-Proofer had a sensitivity of 85.1% and specificity of 73.2%. Testing for HPV type 16 only had sensitivities ranging from 66.0% to 75.5% and specificities from 81.3% to 87.6%. Dual testing with HPV type 16 combined with p16(INK4a) gave a high sensitivity for CIN3+ (78.7% to 98.0%) and specificity for <CIN2 of 58.6% to 81.5%. CONCLUSIONS Triage with sensitive HPV testing assays can substantially reduce the number of unnecessary referrals in women with low grade cytology with virtually no loss of sensitivity. Even greater gains can be made if p16 and type 16 are used, but some cases of CIN2 will be missed. In both cases short term surveillance will be needed.

• Publication year

  2013

• Venue

  European Journal of Cancer

• Publication date

  2013-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejca.2013.01.018PMID 23452990
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluation of 14 triage strategies for HPV DNA‐positive women in population‐based cervical screening

  2012cited by this paper
• Comparison of Seven Tests for High-Grade Cervical Intraepithelial Neoplasia in Women with Abnormal Smears: the Predictors 2 Study

  2012cited by this paper
• HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study

  2011cited by this paper
• High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study.

  2011cited by this paper
• High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV Study

  2011cited by this paper
• HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology : results from the Sentinel Sites study

  2011cited by this paper
• The sensitivity and specificity of p16(INK4a) cytology vs HPV testing for detecting high-grade cervical disease in the triage of ASC-US and LSIL pap cytology results.

  2010cited by this paper
• Process performance of cervical screening programmes in Europe.

  2009cited by this paper
• Comparison of Predictors for High-Grade Cervical Intraepithelial Neoplasia in Women with Abnormal Smears

  2008cited by this paper
• Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases.

  2006cited by this paper
• Role of P16(INK4a) expression in identifying CIN2 or more severe lesions among HPV‐positive patients referred for colposcopy after abnormal cytology

  2006cited by this paper
• Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial.

  2001cited by this paper
• Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group.

  2000cited by this paper
• Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial.

  2000cited by this paper
• ASCUS-LSIL Triage Study

  2000cited by this paper
• Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

  1999cited by this paper

• Evolving HPV diagnostics: current practice and future frontiers

  2025cites this paper
• [High-grade lesions probability in ASCUS HPV positive patient according to HPV type].

  2024cites this paper
• AACC Guidance Document on Cervical Cancer Detection: Screening, Surveillance, and Diagnosis.

  2023cites this paper
• A review of the FDA-approved molecular testing platforms for human papillomavirus.

  2019cites this paper
• RETROSPECTIVE ANALYSIS OF THE TRACKING OF THE UTERINE CERVIX CANCER ON WOMEN UNDER 25 YEARS OLD, DURING 5 YEARS, MADE IN VALENÇA CITY, STATE OF RIO DE JANEIRO BRAZIL

  2019cites this paper
• Triage of low‐grade squamous intraepithelial lesions using human papillomavirus messenger ribonucleic acid tests—A prospective population‐based register study

  2019cites this paper
• HPV genotyping and E6/E7 transcript assays for cervical lesion detection in an Asian screening population-Cobas and Aptima HPV tests.

  2018cites this paper
• Comparison Study of BD Onclarity HPV With digene HC2 High‐Risk HPV DNA Test and Roche Cobas 4800 HPV for Detecting High‐Risk Human Papillomavirus in Japan

  2018cites this paper
• Clinical performance of the Cobas 4800 HPV test and the Aptima HPV assay in the management of women referred to colposcopy with minor cytological abnormalities

  2018cites this paper
• The history of organized screening programs

  2018cites this paper
• The potential of RNA as a target for national screening of pre-cancer

  2018cites this paper
• HPV Screening in the way to cervical cancer elimination

  2018cites this paper
• Elina Virtanen

  2018cites this paper
• Referral population studies underestimate differences between human papillomavirus assays in primary cervical screening

  2017cites this paper
• The BD Onclarity HPV Assay on Samples Collected in SurePath Medium Meets the International Guidelines for Human Papillomavirus Test Requirements for Cervical Screening

  2016cites this paper
• Human papillomavirus mRNA and DNA testing in women with atypical squamous cells of undetermined significance: A prospective cohort study

  2016cites this paper
• Clinical and analytical performance of the BD Onclarity™ HPV assay for detection of CIN2+ lesions on SurePath samples

  2016cites this paper
• Cervical Cancer Screening at a Crossroads: Learnings from the Past Driving Change for the Future

  2016cites this paper
• Correlation between an early 6 and early 7 oncogenes detection method and conventional cytology for cervical cancer screening at Kenyatta National Hospital, Kenya

  2016cites this paper
• Hybrid Capture 2 and cobas human papillomavirus assays perform similarly on SurePath samples from women with abnormalities

  2016cites this paper
• A review of the clinical performance of the Aptima HPV assay.

  2016cites this paper
• Clinical Validation of the BD Onclarity™ HPV Assay Using a Non-Inferiority Test

  2015cites this paper
• High-risk HPV detection and genotyping by APTIMA HPV using cervical samples.

  2015cites this paper
• Comparison of the performance of HPV tests in women with abnormal cytology: results of a study within the NHS cervical screening programme

  2015cites this paper
• Human Papillomavirus Test for Triage of Japanese Women With Low-Grade Squamous Intraepithelial Lesions

  2015cites this paper
• Epidemiology of HPV infection and current status of cervical cancer prevention in Greece: final results of the LYSISTRATA cross-sectional study

  2014cites this paper
• Triaging borderline/mild dyskaryotic Pap cytology with p16/Ki-67 dual-stained cytology testing: cross-sectional and longitudinal outcome study

  2014influential citation
• Disagreement between Human Papillomavirus Assays: An Unexpected Challenge for the Choice of an Assay in Primary Cervical Screening

  2014cites this paper
• Marcadores precoces de la integración del genoma viral del virus del papiloma humano: Utilidad de la detección del mRNA HPV E6/E7 en el cribado del cáncer de cérvix y en el manejo de las lesiones preinvasivas

  2014influential citation
• New diagnostic and prognostic methods to improve the effectiveness of cervical cancer screening

  2014cites this paper
• Triage of HR-HPV Positive Women with Minor Cytological Abnormalities: A Comparison of mRNA Testing, HPV DNA Testing, and Repeat Cytology Using a 4-Year Follow-Up of a Population-Based Study

  2014cites this paper
• Clinical performance of the BD Onclarity HPV assay using an adjudicated cohort of BD SurePath liquid-based cytology specimens.

  2014cites this paper
• Comparison of three human papillomavirus DNA assays and one mRNA assay in women with abnormal cytology.

  2014cites this paper
• Cervical cancer screening: on the way to a shift from cytology to full molecular screening.

  2014cites this paper
• Human papillomavirus detection and genotyping, by HC2, full-spectrum HPV and molecular beacon real-time HPV assay in an Irish colposcopy clinic.

  2014cites this paper
• The Abbott RealTime High Risk HPV test is a clinically validated human papillomavirus assay for triage in the referral population and use in primary cervical cancer screening in women 30 years and older: a review of validation studies.

  2013cites this paper
• The Aptima HPV Assay Fulfills the Cross-Sectional Clinical and Reproducibility Criteria of International Guidelines for Human Papillomavirus Test Requirements for Cervical Screening

  2013cites this paper
• Epidemiology of ocular surface squamous neoplasia in Africa

  2013cites this paper